Opendata, web and dolomites

HAP2 SIGNED

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 HAP2 project word cloud

Explore the words cloud of the HAP2 project. It provides you a very rough idea of what is the project "HAP2" about.

critical    immunology    ifn    infection    bacterial    revolutionize    despite    expertise    illness    ground    hap2    course    academia    ambition    500    microbiome    medicine    cure    frequent    antibiotic    first    immunosuppression    host    dramatic    altering    hospital    respiratory    biological    risk    gamma    axis    fight    infections    physiopathology    drug    patients    urgently    prevention    breaking    pathogen    pneumonia    acquired    world    medical    directed    biomarkers    treatment    alternative    recommendations    uniquely    disease    preventive    supplementation    integrative    pathogens    incidence    predict    hap    social    strategies    drugs    interactions    industry    resistant    survival    genetic    therapies    complete    precision    dysbiosis    diseases    hospitals    capitalising    infectious    clinical    il    variation    stratified    score    12    trials    clinico    reappraisal    placed    episodes    defective    sciences    consumption    interdisciplinary    severe    outcome    30    resistance    omics   

Project "HAP2" data sheet

The following table provides information about the project.

Coordinator
CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES 

Organization address
address: Allee de l'Ile Gloriette 5
city: NANTES
postcode: 44093
website: www.chu-nantes.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 9˙996˙350 €
 EC max contribution 9˙996˙350 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2019-Two-Stage-RTD
 Funding Scheme RIA
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2024-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES FR (NANTES) coordinator 3˙642˙770.00
2    UNIVERSITAT ZURICH CH (ZURICH) participant 1˙510˙587.00
3    UNIVERSITE DE NANTES FR (NANTES CEDEX 1) participant 1˙273˙025.00
4    FUNDACIO CLINIC PER A LA RECERCA BIOMEDICA ES (BARCELONA) participant 841˙365.00
5    STICHTING KATHOLIEKE UNIVERSITEIT NL (NIJMEGEN) participant 785˙000.00
6    NEUMEDICINES INC. US (TUJUNGA CA) participant 732˙127.00
7    BIG DATA SANTE FR (NANTES) participant 477˙328.00
8    UNIVERSITY OF MICHIGAN THE REGENTS OF THE UNIVERSITY OF MICHIGAN US (ANN ARBOR) participant 322˙837.00
9    HOSPICES CIVILS DE LYON FR (LYON) participant 315˙227.00
10    ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON EL (ATHINA) participant 96˙081.00

Map

 Project objective

“HAP2” aims to develop stratified host-directed drugs and biomarkers to enhance the prevention and the treatment of hospital-acquired pneumonia (HAP) and develop precision medicine in infectious diseases. HAP is an infectious disease of major concern in the world, and the most frequent cause of hospital-acquired infections with 500,000 episodes being treated every year in Europe. Despite the development of European recommendations, the incidence remains high, with dramatic medical consequences: existing therapies and preventive measures do not result in the expected favourable outcome (clinical cure and survival) for 30% of patients. HAP are moreover the main cause of antibiotic consumption in European hospitals and are increasingly induced by drug-resistant pathogens. New, alternative and more effective host-targeted strategies are therefore urgently needed to fight antibiotic resistance. The ambition of “HAP2” is to revolutionize the management of HAP: capitalising on the novel concept of critical-illness related immunosuppression altering the host-pathogens interactions, we propose a complete reappraisal of the physiopathology of HAP based on the concept of respiratory dysbiosis. “The HAP2” project will reach two ground-breaking objectives in the field of bacterial infections: first the development of host-targeted approaches for the prevention and the treatment of a severe bacterial infection through the supplementation of the IL-12/IFN-γ axis which is defective in patients at risk of pneumonia; second the development of a clinico-biological score based on an integrative assessment of the host-pathogen interactions and genetic variation, to predict the course of HAP and the response to treatment. Our interdisciplinary consortium, bringing together 10 partners from academia and industry with expertise in clinical trials, immunology, microbiome analysis, omics and social sciences is uniquely placed to achieve this ambition within this 5-year project.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HAP2" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HAP2" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

VANGUARD (2020)

New Generation Cell Therapy: Bioartificial Pancreas to Cure Type 1 Diabetes

Read More  

AutoCRAT (2020)

Automated Cellular Robot-Assisted Technologies for translation of discovery-led research in Osteoarthritis

Read More